Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| hormone refractory metastatic prostate cancer |
|
Prognostic Model for Predicting Survival in Men With Hormone Purpose: To develop and validate a model that can be used to predict the overall survival probability among metastatic hormone-refractory prostate cancer A Contemporary Prognostic Nomogram For Men With Hormone Refractory A Contemporary Prognostic Nomogram For Men With Hormone Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis. Main Category: Prostate / Prostate Cleveland BioLabs Phase II Hormone-Refractory Prostate Cancer About 30000 men die of androgen-independent (hormone-refractory) metastatic prostate cancer each year in the U.S. Taxanes (a group of chemotherapy drugs Combination Chemotherapy in Treating Pain in Patients With Hormone Combination Chemotherapy in Treating Pain in Patients With Hormone Refractory Metastatic Prostate Cancer This study is ongoing, but not recruiting Chemotherapy for hormone-refractory prostate cancer In men with advanced, metastatic prostate cancer, hormone therapy is almost in men with hormone-refractory prostate cancer (HRPC) for many years, 5-Fluorouracil and high dose folinic acid in hormone-refractory BACKGROUND:: The response of hormone-refractory metastatic prostate cancer to chemotherapy is poor. The antitumour activity of single agent 5-fluorouracil A Contemporary Prognostic Nomogram for Men with Hormone-Refractory A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis. Andrew J. Armstrong1, Elizabeth S. Marshall Edwards Inc. - Phenoxodiol However, the majority of cases of prostate cancer eventually become independent of testosterone, at which time they are known as hormone-refractory prostate Reg IV: A Promising Marker of Hormone Refractory Metastatic These data support Reg IV as a candidate marker for hormone refractory metastatic prostate cancer. Key Words: Prostate cancer Á¢ secreted Á¢ marker Á¢ Reg IV IngentaConnect Docetaxel in Hormone-Refractory Metastatic Prostate Docetaxel in Hormone-Refractory Metastatic Prostate Cancer: A Viewpoint by William R. Berry. Author: Berry, William R.1. Source: Drugs, Volume 65, IngentaConnect Docetaxel: In Hormone-Refractory Metastatic The taxoid analogue docetaxel is a potent inhibitor of microtubular depolymerisation and, in hormone-refractory metastatic prostate cancer, it also counters Docetaxel for the treatment of hormone-refractory metastatic Men with hormone refractory metastatic prostate cancer .. For a man with hormone-refractory metastatic prostate cancer who is treated with docetaxel, Hormone-Refractory Prostate Cancer with Bone Metastases - Prostate Newer Concepts in the Treatment of Hormone-Refractory Prostate Cancer with Bone . six patients with metastatic prostate cancer were treated with Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer | Strategic Report | BUY NOW from Piribo.com - á¸8000 / $16114 / Á‚¬11789 - Currently Management of Hormone-Sensitive and Hormone-Refractory Metastatic 41. McLeod DG, Benson RC Jr, Eisenberger MA, et al. The use of flutamide in hormone-refractory metastatic prostate cancer. Cancer. 1993;72:3870-3873. Metastatic And Hormone Refractory Prostate cancer Prostate cancer is the most common male malignancy in Western countries. Increasing usage of screening and changes in treatment practice means companies State-of-the-Art Treatment of Metastatic Hormone-Refractory State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate Cancer. Susan Goodin, Kamakshi V. Rao, Robert S. DiPaola. The Cancer Institute of New Hormone-Refractory Metastatic Prostate Cancer What is the best treatment for a 60-year-old man with prostate cancer that has metastasized to the spine and who was already treated with leuprolide, eMedicine - Prostate Cancer: Metastatic and Advanced Disease For metastatic prostate cancer, radiation is also applied for palliative purposes. It is used for patients with hormone-refractory disease with painful bone |
| hormone refractory metastatic prostate cancer |
|
homeopathy and prostate cancer laparoscopic radical prostatectomy ontario lateral lobe prostate light laser prostatectomy |